ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Indrayani Biotech filed its quarterly shareholding pattern for 30 September 2026. Promoter group holds 32.89% of equity; this is routine compliance with no corporate event.
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
Indrayani Biotech's 34th AGM is set for 30 November 2026, with book closure from 24 to 30 November. Remote e-voting runs 27 to 29 November 2026.
Indrayani Biotech appointed Ms. N.S. Poornima as Secretarial Auditor and accepted the resignation of Company Secretary C.S. Shanmuga Sundar effective 2 Nov 2026. The KMP departure due to personal health is the material change.
Indrayani Biotech allotted 83,64,036 rights equity shares at Rs 15 (75,03,333 fully paid) and Rs 3.75 (8,60,703 partly paid). Issue receipts total about Rs 11.58 Crore.
Indrayani Biotech's committee allotted 83,64,036 partly paid rights shares at Rs.15 each, worth about Rs.12.55 crore. Application money of Rs.3.75 per share has been received.
Indrayani Biotech Ltd has scheduled a Board meeting for November 06, 2026. The meeting will primarily consider the notice for the company's 34th Annual General Meeting.
Indrayani Biotech appointed Ms. N. S. Poornima as Secretarial Auditor for FY 2025-26 to fill a casual vacancy. Company Secretary C.S. Shanmuga Sundar's resignation took effect on 2 November 2026.
Indrayani Biotech received a tax recovery notice for outstanding demands totaling ₹1.17 Crore for various assessment years, for which the company has filed responses.
Independent Director Mr. K.S. Vaidyanathan has resigned from the Board of Indrayani Biotech Limited, effective October 13, 2026, due to personal reasons.
Indrayani Biotech Limited submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Indrayani Biotech Ltd reported revenue from operations of ₹37.7 Cr (+29.6% YoY) and net profit of ₹0.5 Cr (+150.0% YoY) for Q1 FY27.
Indrayani Biotech sold shares of its subsidiary, Dindigul Farm Product Limited, to the open market. This divestment marks a reduction in the company's subsidiary holding.
Indrayani Biotech will hold a board meeting on October 7, 2026, to consider the company's unaudited financial results for the quarter ended June 30, 2026.